Beaven Simon W, Tontonoz Peter
Department of Medicine, Division of Digestive Diseases, Howard Hughes Medical Institute, University of California, Los Angeles, California 90095-1662, USA.
Annu Rev Med. 2006;57:313-29. doi: 10.1146/annurev.med.57.121304.131428.
Dyslipidemia is the sine qua non of atherosclerosis, but it is also strongly associated with the metabolic syndrome, obesity, diabetes, and fatty liver disease. The molecular basis for future therapies requires understanding the pivotal role of nuclear hormone receptors in lipid and inflammatory homeostasis. This review summarizes evidence that the liver X receptor (LXR) and peroxisome proliferator-activated receptor (PPAR) are key transcriptional regulators in lipid metabolism. Additionally, their effects on glucose homeostasis and inflammation make LXR and PPAR signaling networks attractive molecular targets for managing lipid-related diseases.
血脂异常是动脉粥样硬化的必要条件，但它也与代谢综合征、肥胖、糖尿病和脂肪性肝病密切相关。未来治疗的分子基础需要了解核激素受体在脂质和炎症稳态中的关键作用。本综述总结了肝脏X受体（LXR）和过氧化物酶体增殖物激活受体（PPAR）是脂质代谢关键转录调节因子的证据。此外，它们对葡萄糖稳态和炎症的影响使LXR和PPAR信号网络成为治疗脂质相关疾病有吸引力的分子靶点。
